{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:37:22Z","timestamp":1787236642277,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","ajog.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ajog.2024.07.044","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:33:54Z","timestamp":1722886434000},"page":"194.e1-194.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-3936","authenticated-orcid":false,"given":"Floriane","family":"Jochum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lise","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gougis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Querleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Lecointre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Lecuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherif","family":"Akladios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2024.07.044_bib1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/ijgc-2020-002081","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?","volume":"30","author":"Fotopoulou","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2024.07.044_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00404-023-06948-3","article-title":"Management of patients with advanced epithelial ovarian cancer: a European survey","volume":"308","author":"Jochum","year":"2023","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2024.07.044_bib3","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1245\/s10434-019-07516-3","article-title":"Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome","volume":"26","author":"Hall","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejogrb.2018.02.029","article-title":"Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands","volume":"223","author":"Timmermans","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2024.07.044_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2024.07.044_bib6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2024.07.044_bib7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2024.07.044_bib8","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib9","first-page":"CD005343","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer","volume":"7","author":"Coleridge","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2024.07.044_bib10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cancers12030768","article-title":"30 years of experience in the management of Stage III and IV epithelial ovarian cancer: impact of surgical strategies on survival","volume":"12","author":"Delga","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2024.07.044_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial","volume":"130","author":"Onda","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2024.07.044_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s10147-023-02329-7","article-title":"Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study","volume":"28","author":"Nagao","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/ijgc-2023-005065","article-title":"Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis","volume":"34","author":"Kim","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2024.07.044_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","author":"Colombo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2024.07.044_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12967-020-02295-y","article-title":"Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival","volume":"18","author":"Dabi","year":"2020","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.ajog.2024.07.044_bib16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/ijgc-2018-000100","article-title":"Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer","volume":"29","author":"Timmermans","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2024.07.044_bib17","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data","volume":"49","author":"Maringe","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ajog.2024.07.044_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ajog.2024.07.044_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajog.2024.07.044_bib20","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2024.07.044_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ygyno.2016.06.013","article-title":"FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited","volume":"142","author":"Ataseven","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib22","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ejca.2012.01.031","article-title":"Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?","volume":"48","author":"Trop\u00e9","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2024.07.044_bib23","article-title":"A\u00a0retrospective analysis for investigating the relationship between FIGO stage IVA\/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/aogs.14319","article-title":"Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer","volume":"101","author":"S\u00f8rensen","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajog.2024.07.044_bib25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1245\/s10434-011-2100-x","article-title":"Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer","volume":"19","author":"Rauh-Hain","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/0284186X.2017.1400691","article-title":"Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease \u2013 a Swedish Gynecologic Cancer Group (SweGCG) study","volume":"57","author":"Hjerpe","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2017.07.124","article-title":"Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?","volume":"147","author":"Nasioudis","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib28","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.athoracsur.2006.01.068","article-title":"Gynecologic cancers: factors affecting survival after pulmonary metastasectomy","volume":"81","author":"Clavero","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ajog.2024.07.044_bib29","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1245\/s10434-009-0486-5","article-title":"Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery","volume":"16","author":"Lim","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2015.05.003","article-title":"The impact of pleural disease on the management of advanced ovarian cancer","volume":"138","author":"Escayola","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2024.07.044_bib31","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.3390\/cancers12082156","article-title":"Brain metastases from ovarian cancer: current evidence in diagnosis, treatment, and prognosis","volume":"12","author":"Borella","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2024.07.044_bib32","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"29","author":"Reuss","year":"2019","journal-title":"Int J Gynecol Cancer"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937824008184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937824008184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:51:01Z","timestamp":1737381061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937824008184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0002937824008184"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2024.07.044","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2024.07.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}